SEC Form 4Coverage since Jun 23, 2026
$VERA insider trading
Over the last 12 months, Vera Therapeutics insiders reported no purchases and 2 sales totaling $2.7M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $2.7M 2 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $VERA · 12Mvia TradingView
Top insiders · 12m
Fordyce MarshallPRESIDENT AND CEO2× · $2.7M
All insider trades
2 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Fordyce MarshallPRESIDENT AND CEO · O·D | ▼ Sale | 46,250 | $42.3 | $2.0M | -23.3% | plan · 4 tranches |
| Jun 23, 2026 | Fordyce MarshallPRESIDENT AND CEO · O·D | ▼ Sale | 18,500 | $37.93 | $702K | -8.5% | plan · 2 tranches |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $VERA feed.